Patents by Inventor Ian Tarpey

Ian Tarpey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230355741
    Abstract: The present invention provides new vaccines for felines and ferrets to aid in reducing shedding of severe acute respiratory syndrome coronavirus 2 by infected felines or ferrets. Methods of making and using the vaccines alone or in combinations with other protective agents are also provided.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 9, 2023
    Applicant: Intervet Inc.
    Inventors: Mark A. Mogler, Ian Tarpey
  • Patent number: 11730809
    Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: August 22, 2023
    Assignee: Intervet Inc.
    Inventors: Zhichang Xu, Rhonda LaFleur, Ian Tarpey
  • Patent number: 11680097
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: June 20, 2023
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Patent number: 11596687
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: March 7, 2023
    Assignee: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Ian Tarpey, Iwan Verstegen, Paulus Jacobus Antonius Sondermeijer, Paul Vermeij
  • Publication number: 20230012140
    Abstract: The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.
    Type: Application
    Filed: December 17, 2020
    Publication date: January 12, 2023
    Applicant: Intervet Inc.
    Inventors: Rhonda L. LaFleur, Jennifer C. Dant, Ian Tarpey, Zhichang Xu
  • Publication number: 20220389114
    Abstract: The present invention discloses antibodies including caninized antibodies against canine PD-L1 with specific properties. The present invention further relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes. The invention further discloses the use of the caninized anti-canine PD-LI antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: August 15, 2022
    Publication date: December 8, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Patent number: 11447561
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: September 20, 2022
    Assignee: Intervet, Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Publication number: 20220251208
    Abstract: The present invention provides caninized murine antibodies against canine CTLA-4 that have specific sequences and a high binding affinity for canine CTLA-4. The present invention further provides epitopes of canine CTLA-4 for caninized murine antibodies against canine CTLA-4.5 The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals.
    Type: Application
    Filed: July 15, 2020
    Publication date: August 11, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Publication number: 20220251209
    Abstract: The present invention provides caninized anti-human CTLA-4 antibodies that have specific sequences and a high binding affinity for canine CTLA-4. The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals.
    Type: Application
    Filed: July 15, 2020
    Publication date: August 11, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Publication number: 20220211839
    Abstract: The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.
    Type: Application
    Filed: March 18, 2022
    Publication date: July 7, 2022
    Applicant: Intervet Inc.
    Inventor: Ian Tarpey
  • Publication number: 20220204615
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: January 12, 2022
    Publication date: June 30, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Publication number: 20220125915
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.
    Type: Application
    Filed: June 15, 2017
    Publication date: April 28, 2022
    Applicant: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Ian Tarpey, Iwan Verstegen, Paulus Jacobus Antonius Sondermeijer, Paul Vermeij
  • Patent number: 11311616
    Abstract: The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 26, 2022
    Assignee: Intervet Inc.
    Inventor: Ian Tarpey
  • Publication number: 20220088187
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: Intervet Inc.
    Inventors: Stephanie M. Cook, Mohamad Morsey, Ian Tarpey
  • Patent number: 11248047
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 15, 2022
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Patent number: 11229699
    Abstract: The present invention provides new feline calicivirus vaccines, including multivalent vaccines. The present invention also provides methods of making and using the vaccines.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: January 25, 2022
    Assignee: Intervet Inc.
    Inventor: Ian Tarpey
  • Patent number: 11229698
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: January 25, 2022
    Assignee: Intervet Inc.
    Inventors: Stephanie M. Cook, Mohamad Morsey, Ian Tarpey
  • Publication number: 20220008532
    Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 13, 2022
    Applicant: Intervet Inc.
    Inventors: Zhichang Xu, Rhonda LaFleur, Ian Tarpey
  • Patent number: 11167027
    Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: November 9, 2021
    Assignee: Intervet Inc.
    Inventors: Zhichang Xu, Rhonda LaFleur, Ian Tarpey
  • Publication number: 20210177961
    Abstract: The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 17, 2021
    Applicant: Intervet Inc.
    Inventor: Ian Tarpey